GCAR1

BIOLOGICAL5 trials

Sponsors

AHS Cancer Control Alberta, University of Calgary, Canadian Cancer Trials Group

Conditions

Alveolar Soft Part SarcomaAlveolar Soft Part Sarcoma (ASPS)Renal Cell CarcinomaSarcomaTriple Negative Breast Cancer

Early Phase 1

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

Active, not recruitingNCT06789081

AHS Cancer Control AlbertaAlveolar Soft Part Sarcoma

Start: 2024-02-01End: 2028-03-01Target: 1Updated: 2026-03-23

CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma

Active, not recruitingNCT06813417

University of CalgaryAlveolar Soft Part Sarcoma (ASPS), Sarcoma

Start: 2025-01-30End: 2030-01-30Updated: 2025-04-10

GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

CompletedNCT06827886

AHS Cancer Control AlbertaAlveolar Soft Part Sarcoma

Start: 2023-09-06End: 2024-09-09Updated: 2025-07-23

A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma

Active, not recruitingNCT07104682

University of CalgaryAlveolar Soft Part Sarcoma (ASPS), Sarcoma

Start: 2025-08-21End: 2027-01-19Target: 1Updated: 2026-08-04

Phase 1

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

RecruitingNCT07297667

Canadian Cancer Trials GroupAlveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer

Start: 2026-08-30End: 2033-09-01Target: 30Updated: 2026-09-17

Related Papers

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

2026-07-01